Why Vaccine.GRID is needed


Rapid quantification of vaccine effects thoughout life-cycle

Vaccines are increasingly made available more widely and tailored to special populations. Planning a large immunization program is much facilitated by reliable background incidence rates of the target disease. Timely quantification of vaccine coverage, effectiveness and safety is pivotal for continuous benefit-risk assessments throughout the vaccine’s life-cycle.


Expanded capacity to monitor vaccine effects globally

Vaccine safety concerns may derail immunization programs and often are based on rare but serious adverse events. Large-scale collaboration across countries with different patterns of vaccine use is key to the rapid quantification of the benefits and risks of vaccines on a population level. Furthermore, the globalization of manufacturing and the increasing introduction of new vaccines into countries outside Europe and North America require expanded capacity to monitor their safety.


Federation of fragmented resources by cutting edge technology

Due to the current focus on information and computer technology to provide safer and more effi cient health care delivery, the amount of electronic health records and other electronic health care data is increasing exponentially. These data are extremely useful for quantification of vaccine effects. By linking fragmented resources, the scale and scope of the research can be extended to the global level. In our partnership, we capitalize on these possibilities and tailor the technologies to the needs of assessing vaccine benefit-risk profiles.



Why Vaccine.GRID is needed



We are a global research network. We are a non-profit partnership providing high quality vaccine safety information. We do not advocate for specific vaccines and do not receive funding from specific manufactures. We are a scientifically independent network consisting mainly of volunteers. VACCINE.GRID is a federated network of leading public health, patient care, and academic organizations experienced and dedicated to implementing innovative and distributed vaccine effect research. VACCINE.GRID is a globally oriented network, aiming at overcoming the boundaries of institutions, nations and continents to use the best data possible and inform vaccine benefit and risk assessments across the globe.



The global VACCINE.GRID network enables outcome driven collaboration of public health, patient care and academic organizations. The VACCINE.GRID Foundation serves as the hosting legal entity and connects public and private contractual partners with the the VACCINE.GRID researchers.



The Collaboration abides by the following guiding principles and the constitution and regulation of the partnership:

  • Collaboration: To work together effectively by promoting good internal andexternal communications through open decision making and teamwork.
  • Worldwide Participation: To promote global participation to meet global needs.

  • Multidisciplinary Approach: To involve people of different skills and backgrounds, to establish synergies and build on individual contributions.
  • Accessibility: To allow broad participation in the work of VACCINE.GRID
by minimizing obstacles to contributing while recognizing differences in suitability.
  • Relevance: To offer solutions for public and private vaccine concerns.
  • Transparency: To be open and accountable about actions performed.
  • Independence: To safeguard scientific freedom and integrity by adhering to the EnCEPP code of conduct.
  • Responsibility: To maintain continuity of responsibility for VACCINE.GRID action.




The foundation Vaccine.GRID



VACCINE.GRID is hosted by its Foundation. The Foundation was set up to serve a critical need by being able to engage in contracts with both public and private sponsors including vaccine manufacturers while maintaining independence and transparency. In 2012, the Brighton Collaboration Foundation in Switzerland established the VACCINE.GRID Foundation as a separate and independent legal entity to maintain financial and scientific independence of the Brighton Collaboration.



A Team standing for the independence of the Foundation and the Network to promote high quality vaccine research, independent of vested interests. The Board works entirely voluntary to foster the attainment of the Foundations Vision and Mission.



The Foundation adheres to the highest governance principles and is supervised directly by the Swiss government. It subject to the laws of Switzerland. It is directly supervised by the section of the Swiss Government assigned to Not-For-Profit Organizations.

All corporate powers of the Foundation are exercised by or under the authority of the Foundation Board of Directors. The Board is in charge of all powers not conferred to other executive bodies of the Foundation by its articles and by-laws. The first Board was appointed by the Founder to then constitute and complete itself. The Board of Directors currently consists of 3 members with voting rights. It elects a President, a Vice-President and a Treasurer among its members as well as the other executive bodies: the Auditor and the Scientific Advisory Committee.

The Foundation Board stands for the independence of the Foundation to promote high quality vaccine research, independent of vested interests. The Board works entirely voluntary and advises the Management Team to realize the purpose of the Foundation. The external auditor reviews the financial reports of the organization and ensures compliance with Swiss legal requirements. Price Waterhouse Coopers was re-elected as the external auditor.



The Vaccine.GRID board of directors


The Foundation Board creates strategies that help our contractual partners and the VACCINE.GRID scientists achieve common goals by:

  • Continuously recruiting new scientific partners to the network
  • Guiding the organizational direction and deteriming the lang term strategy
  • Reviewing and approving VACCINE.GRID policy and regulations
  • Evaluating network goals and performance
  • Reviewing compliance with the guiding principles




Miriam Sturkenboom

Professor of Pharmaco-epidemiology






Steve Black

Professor, Center for Global Child Health

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, USA



Daniel Weibel

PhD, Assistant professor

Erasmus University Medical Center